Spero Therapeutics Inc (SPRO)
0.9597
-0.04
(-3.84%)
USD |
NASDAQ |
Dec 20, 16:00
0.9568
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Revenue (Quarterly): 7.819M for Sept. 30, 2024
Revenue (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (Quarterly) Benchmarks
| CytomX Therapeutics Inc | 33.43M |
| Castle Biosciences Inc | 85.78M |
| Arbutus Biopharma Corp | 1.339M |
| PTC Therapeutics Inc | 196.79M |
| Equillium Inc | 12.16M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -17.15M |
| Total Expenses (Quarterly) | 26.41M |
| EPS Diluted (Quarterly) | -0.32 |
| Enterprise Value | -23.97M |
| Profit Margin (Quarterly) | -219.3% |
| Earnings Yield | 8.34% |
| Normalized Earnings Yield | 8.336 |